BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33220820)

  • 1. [Treatment for refractory non-neurogenic overactive bladder].
    Gamé X; Phé V
    Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy-refractory overactive bladder: alternative treatment approaches].
    Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
    Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evaluation and management of refractory neurogenic overactive bladder.
    Kurpad R; Kennelly MJ
    Curr Urol Rep; 2014 Oct; 15(10):444. PubMed ID: 25118853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie J; Wilson DI; Herbison GP; Wilson D
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
    Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
    Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
    Leicht W; Hampel C; Thüroff J
    Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome].
    Deffieux X; Fatton B; Denys P; Chartier-Kastler E; Amarenco G; Haab F; Costa P; Game X; Karsenty G; Saussine C; Ballanger P; Le Normand L; Ruffion A; Hermieu JF; Cosson M
    J Gynecol Obstet Biol Reprod (Paris); 2014 Oct; 43(8):572-80. PubMed ID: 25087018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
    Kantartzis K; Shepherd J
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of overactive bladder in women].
    Peyronnet B; Rigole H; Damphousse M; Manunta A
    Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections].
    Levy J; Le Breton F; Jousse M; Haddad R; Verollet D; Guinet-Lacoste A; Amarenco G
    Prog Urol; 2014 Oct; 24(12):744-9. PubMed ID: 25199730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
    Lacout M; Guinet-Lacoste A; Popoff M; Verollet D; Lebreton F; Amarenco G
    Prog Urol; 2015 Sep; 25(11):642-8. PubMed ID: 26094097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy.
    Bhide AA; Tailor V; Fernando R; Khullar V; Digesu GA
    Int Urogynecol J; 2020 May; 31(5):865-870. PubMed ID: 31853597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
    Zahner PM; Giusto LL; Goldman HB
    Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
    Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
    Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
    Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
    Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.